Alopecia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Alopecia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Alopecia - Pipeline Review, H2 2014', provides an overview of the Alopecia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Alopecia Overview 8
Therapeutics Development 9
Pipeline Products for Alopecia - Overview 9
Pipeline Products for Alopecia - Comparative Analysis 10
Alopecia - Therapeutics under Development by Companies 11
Alopecia - Therapeutics under Investigation by Universities/Institutes 13
Alopecia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Alopecia - Products under Development by Companies 17
Alopecia - Products under Investigation by Universities/Institutes 18
Alopecia - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Valeant Pharmaceuticals International, Inc. 20
Taisho Pharmaceutical Co., Ltd. 21
AntiCancer, Inc. 22
Panacea Biotec Limited 23
C3 Jian, Inc 24
ProCertus BioPharm Inc. 25
AndroScience Corporation 26
Hygeia Therapeutics, Inc. 27
Kuhnil Pharmaceutical Co., Ltd. 28
Lee's Pharmaceutical Holdings Limited 29
vida therapeutics inc. 30
Alopecia - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
DHL-HisZnNa - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
abatacept - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CB-0301 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ProDermaCel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
calcitriol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ZK-003 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HYG-430 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HYG-420 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HYG-410 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ASCJ-9 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KI-1104 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptide for Alopecia - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
V-2248 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Peptide for Alopecia and Chemotherapy Effects - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Lipo-4MA - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KI-1105 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Drug to Activate P2Y5 Receptor for Alopecia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Alopecia - Recent Pipeline Updates 65
Alopecia - Dormant Projects 69
Alopecia - Discontinued Products 70
Alopecia - Product Development Milestones 71
Featured News & Press Releases 71
Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth 71
Feb 04, 2013: RepliCel To Meet With German Competent Authority On Its RCH-01 Autologous Hair Cell Manufacturing Process 71
Nov 07, 2012: RepliCel Completes First Pre-Filing Review With German Competent Authority On RCH-01 Autologous Hair Cell Manufacturing Process 72
Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows 72
Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 73
Apr 11, 2012: FDA Announces Changes To Professional Labels For Propecia 73
Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia 74
Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB-03-01 74
Oct 06, 2009: R-Tech Ueno Initiates Early Phase II Clinical Trial For RK-023 75
Jul 16, 2009: Notification Of The Completion Of Phase I Clinical Study Of RK-023 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 7

List of Tables
Number of Products under Development for Alopecia, H2 2014 9
Number of Products under Development for Alopecia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Alopecia - Pipeline by Bristol-Myers Squibb Company, H2 2014 19
Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 20
Alopecia - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 21
Alopecia - Pipeline by AntiCancer, Inc., H2 2014 22
Alopecia - Pipeline by Panacea Biotec Limited, H2 2014 23
Alopecia - Pipeline by C3 Jian, Inc, H2 2014 24
Alopecia - Pipeline by ProCertus BioPharm Inc., H2 2014 25
Alopecia - Pipeline by AndroScience Corporation, H2 2014 26
Alopecia - Pipeline by Hygeia Therapeutics, Inc., H2 2014 27
Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2014 28
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 29
Alopecia - Pipeline by vida therapeutics inc., H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Alopecia Therapeutics - Recent Pipeline Updates, H2 2014 65
Alopecia - Dormant Projects, H2 2014 69
Alopecia - Discontinued Products, H2 2014 70